Loading...
Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for >/=24 weeks in Europe.
de Bono, J Chowdhury, S Feyerabend, S Elliott, Tony Grande, E Melhem-Bertrandt, A Baron, B Hirmand, M Werbrouck, P Fizazi, K
de Bono, J
Chowdhury, S
Feyerabend, S
Elliott, Tony
Grande, E
Melhem-Bertrandt, A
Baron, B
Hirmand, M
Werbrouck, P
Fizazi, K
Citations
Altmetric:
Abstract
Enzalutamide and abiraterone acetate plus prednisone, which target the androgen receptor axis, have expanded the treatment of advanced prostate cancer. Retrospective analyses suggest some cross-resistance between these two drugs when used sequentially, but robust, prospective studies have not yet been reported.
Affiliation
Description
Date
2017-08-22
Publisher
Collections
Keywords
Type
Article
Citation
Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for >/=24 weeks in Europe. 2017 Eur Urol